Reviva Pharmaceuticals Warrants
RVPHW
RVPHW was delisted on the 12th of December, 2025.
6 hedge funds and large institutions have $979K invested in Reviva Pharmaceuticals Warrants in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 4 closing their positions.
25% less funds holding
Funds holding: 8 → 6 (-2)
32% less capital invested
Capital invested by funds: $1.45M → $979K (-$468K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$79.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ASM
ATW SPAC Management
New York
|
-$438K |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$438K |
| 3 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$890 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
1
BlueCrest Capital Management
St Helier,
Jersey
| $427K | – | – | – |
|
|
AA
2
AQR Arbitrage
Greenwich,
Connecticut
| $398K | -$890 | -2,238 | -2% |
|
|
6CM
3
683 Capital Management
New York
| $70K | +$79.5K | +200,000 | New |
|
4
Walleye Capital
New York
| $31K | – | – | – |
|
|
AI
5
Arena Investors
Purchase,
New York
| $29.8K | +$33.8K | +85,000 | New |
|
6
Walleye Trading
New York
| $23K | – | – | – |
|
|
ASM
7
ATW SPAC Management
New York
| – | -$438K | -107,701 | Closed |
|
|
BFM
8
Boothbay Fund Management
New York
| – | -$438K | -107,701 | Closed |
|
RVPHW Hedge Fund Activity: Q4 2021 in Review
6 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Reviva Pharmaceuticals Warrants (RVPHW) for Q4 2021, worth a combined $979K — down 32% from $1.45M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of RVPHW and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $79.5K. The largest seller was ATW SPAC Management, exiting entirely with an estimated $438K sold.
- 6 institutional investors held Reviva Pharmaceuticals Warrants (RVPHW) as of Q4 2021, down from 8 in Q3 2021.
- Funds reported $979K of Reviva Pharmaceuticals Warrants stock for Q4 2021, down 32% quarter-over-quarter.
- 2 funds opened new Reviva Pharmaceuticals Warrants positions in Q4 2021 and 4 closed out, a net change of -2 holders.
- The largest Reviva Pharmaceuticals Warrants buyer in Q4 2021 was 683 Capital Management, an estimated $79.5K added.
- The largest Reviva Pharmaceuticals Warrants seller in Q4 2021 was ATW SPAC Management, an estimated $438K sold.
Based on aggregated 13F filings for Q4 2021.